Packaging of the PRODUCT Sample Clauses

Packaging of the PRODUCT. 5.1 Individual bags of high-density polyethylene spun into continuous fibres (Tyvek®) to prevent the silica from dusting. OR 5.2 Package in accordance with US military specification MIL-P-116, Method II, modified to eliminate the evacuation process and desiccant. Barrier Bags will meet or exceed the requirements of Type III, Class E. Humidity indicators are not required. This specification requires that the dessicant material be sealed in a water vapour-proof, grease-proof heat-sealable Barrier Bag of size sufficient to enclose the desiccant package necessary to dehydrate the chosen container size. Note that silica gel conforming to MIL-D-3464 will be included in packages of products expected to be subjected to prolonged storage in tropical geographical regions
Sample 1Sample 2
AutoNDA by SimpleDocs
Packaging of the PRODUCT. 3.5.1 FRESENIUS KABI will complete qualification, procurement, incoming inspection, storage, sampling, testing, and release of Primary and Secondary Packaging Materials and Printed Components according to approved Specifications. X 3.5.2 FRESENIUS KABI will follow written procedures describing the identification, quarantine, handling, sampling, testing and approval or rejection of the PRODUCT, Printed Components, and Primary and Secondary Packaging Materials. X 3.5.3 FRESENIUS KABI will qualify Packaging vendors per FRESENIUS KABI SOPs. FRESENIUS KABI shall have sufficient documentation in place to justify any reduced sampling and testing. FRESENIUS KABI will only use approved Packaging manufacturers, distributors, and suppliers. X 3.5.4 FRESENIUS KABI will ensure that the PRODUCT is Packaged, inspected, and held according to FRESENIUS KABI’ s procedures and Packaging instructions, and fulfills the PRODUCT Specification. X 3.5.5 FRESENIUS KABI will control Specifications for Primary and Secondary Packaging Materials and provide reference copies to CSI. X 3.5.6 CSI will control content including artwork and labeling text Specifications of Printed Components. X 3.5.7 FRESENIUS KABI will retain samples of Primary Packaging Materials for one year past expiry of last lot of the PRODUCT contained in the Primary Packaging Materials. X 3.5.8 FRESENIUS KABI will complete reconciliation of Primary Packaging Material and Printed Components after all critical process steps. FRESENIUS KABI will perform component accountability per its approved SOPs. Any reconciliation outside of pre-established limits must be investigated and a copy of the investigation included in the reconciliation. X 3.5.9 FRESENIUS KABI will create and maintain the BOM for PRODUCT Packaging and provide copies of the BOM to CSI. X 3.5.10 FRESENIUS KABI will create and maintain master Packaging instructions in accordance with the PRODUCT Specifications and/or CSI instructions and provide official copies to CSI when the documents are revised. X 3.5.11 FRESENIUS KABI will maintain all executed master Packaging instructions and associated PRODUCT documentation for a minimum of one year beyond expiry date of the PRODUCT. FRESENIUS KABI, if applicable, shall keep validation batch production records permanently. X 3.5.12 FRESENIUS KABI will provide CSI with customer samples of Printed Components, as requested. X
Sample 1
Packaging of the PRODUCT. The parties agree that the product to be supplied will be packed in SLS containers. Each SLS container will contain approximately 16 metric tons of product. Similarly, the parties agree that while the dissolution station is not delivered and commissioned, the product will be packed in wood boxes with PP-big-bag or super inside coated bags with PE liner or polyethylene membrane, previously approved by the United Nations in pallets containing 1,000 kg net weight of the product. The provision mentioned in the preceding paragraph shall apply in case there are not enough SLS containers in time for shipping the product to be supplied to "Molimentales". The contracting parties agree that "Molimentales" shall be liable for storing the wood boxes and bags or containers for disposal, in each case, in a safe and responsible manner and in accordance with the current regulations in terms of Mexican law and its rules and regulations.
Sample 1
Packaging of the PRODUCT. 3.5.1 Baxter will complete qualification, procurement, incoming inspection, storage, sampling, testing, and release of Primary and Secondary Packaging Materials and Printed Components according to approved Specifications. X 3.5.2 Baxter will follow written procedures describing the identification, quarantine, handling, sampling, testing and approval or rejection of the PRODUCT, Printed Components, and Primary and Secondary Packaging Materials. X 3.5.3 Baxter will qualify Packaging vendors per Baxter SOPs. Baxter shall hav sufficient documentation in place to justify any reduced sampling and testing. Baxter will only use approved Packaging manufacturers, distributors, and suppliers. X 3.5.4 Baxter will ensure that the PRODUCT is Packaged, inspected, and held according to Xxxxxx’x procedures and Packaging instructions, and fulfills the PRODUCT Specification. X 3.5.5 Baxter will control Specifications for Primary and Secondary Packaging Materials and provide reference copies to EKR. X 3.5.6 EKR will control content including artwork and labeling text Specifications of Printed Components. X
Sample 1
Packaging of the PRODUCT. 5.1 Individual bags of high-density polyethylene spun into continuous fibres (Tyvek®) to prevent the silica from dusting. OR 5.2 Package in accordance with US military specification MIL-P-116, Method II, modified to eliminate the evacuation process and desiccant. Barrier Bags will meet or exceed the requirements of Type III, Class
Sample 1
Packaging of the PRODUCT. 8.1 The Product will be supplied in EUSA's packaging and livery. The packaging and all package inserts will be in either Greek or English language.
Sample 1
Packaging of the PRODUCT. (a) Evanx xxxl supply the Product in packed form as agreed by the Parties at the time of placing an order and approved by the FDA. (b) The Product will be supplied in Evanx xxxkaging, subject to the provisions of Section 3.4. The packaging and all package inserts will be in the English language. OraVax shall be responsible for ensuring that the specifications for packaging and packaging inserts comply with the requirements of the FDA. Any subsequent modification required by the FDA shall be made known to Evanx xx writing by OraVax within ten (10) days of the time which OraVax first becomes aware of it. The packaging shall include, in a form acceptable to Evanx, xx acknowledgment that the Product is manufactured by Evanx xxx that the Trademarks are registered trademarks of Evanx.
Sample 1
AutoNDA by SimpleDocs

Related to Packaging of the PRODUCT

  • Product Labeling The labeling of all Licensed Products sold or offered for sale under this Agreement shall expressly state that the Licensed Product is manufactured under a license from the Medicines Patent Pool.

  • Manufacture of Products All Products marketed through Grantor's Web ------------------------- Site shall be manufactured, packaged, prepared, and shipped in accordance with the specifications and requirements described on Exhibit A hereto as it may be modified from time to time. Quality control standards relating to the Product's weight, color, consistency, micro-biological content, labeling and packaging are also set forth on Exhibit A. In the event that Exhibit A is incomplete, Products shall be manufactured and shipped in accordance with industry standards.

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

  • Packaging and Labeling Seller shall properly xxxx, xxxx, and ship Goods and provide Buyer with shipment documentation showing the Order number, Seller’s identification number for the subject Goods, the quantity of goods in shipment and the number of cartons or containers in the shipment.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Labeling Upon request, Lessee will xxxx the Equipment indicating Lessor's interest with labels provided by Lessor. Lessee will keep all Equipment free from any other marking or labeling which might be interpreted as a claim of ownership.

  • Product Sales Subject to Sections 10.3(c) and 10.3(d), Licensee agrees that it will not sell, offer for sale, or assist third parties (including Affiliates) in selling Product except for the sale and offer for sale of (A) TAF Product, TAF Combination Product, TDF Product and TDF Combination Product for use in the Field and in the countries of the TDF-TAF Territory, (B) COBI Product and COBI Combination Product for use in the Field and in the countries of the COBI Territory, and (C) EVG Product, EVG Combination Product and Quad Product for use in the Field and in the countries of the EVG-Quad Territory.‌ (i) Licensee agrees that during the period in which the Patents are valid and enforceable (on a Product-by-Product basis) it will prohibit its Distributors from selling Product (A) to any other wholesaler or distributor, (B) outside the Territory for which Licensee is licensed for sale of such Product pursuant to Section 2.2, or (C) for any purpose outside the Field. (ii) Licensee agrees that it will not administer the TAF Quad to humans, or sell the TAF Quad until Gilead has obtained marketing approval for the TAF Quad from the FDA. Licensee agrees that it will not administer EVG to humans, or sell Products containing EVG until Gilead has obtained marketing approval for an EVG Product from the FDA. Licensee agrees that it will not administer COBI to humans, or sell Products containing COBI until Gilead has obtained marketing approval for a COBI Product from the FDA. Licensee agrees that it will not administer TAF to humans, or sell Products containing TAF until Gilead has obtained marketing approval for a TAF Product from the FDA. If Gilead obtains marketing approval from the FDA for any Quad Product or a Combination Product containing TAF, COBI or EVG (“Approved Combination Product”) prior to obtaining marketing approval for a TAF Product, EVG Product or COBI Product from the FDA, then Licensee will be allowed to administer such Quad Product or such Approved Combination Product to humans, and sell such Quad Product or such Approved Combination Product from and after the date of such marketing approval from the FDA, but will not (A) administer to humans or sell Combination Products containing EVG other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for an EVG Product, or (B) administer to humans or sell Combination Products containing COBI other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a COBI Product or (C) administer to humans or sell Combination Products containing TAF other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a TAF Product.

  • Packaging Tangible product shall be securely and properly packed for shipment, storage, and stocking in appropriate, clearly labeled, shipping containers and according to accepted commercial practice, without extra charge for packing materials, cases, or other types of containers. All containers and packaging shall become and remain Customer’s property.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time. (b) The Supplier shall not change any process, material, component, packaging or manufacturing location without the Purchaser’s express prior written approval.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!